Ultime notizie per Vivos (OTC:RDGL) Azioni

Vivos Inc is a radiation oncology medical device company. It is engaged in the development of RadioGel which is a brachytherapy device comprising highly insoluble particles delivered by needle injection using a water-polymer composite for high-dose treatment of non-resectable solid tumors. IsoPet is another product of the company used for the treatment of solid tumors in animals. The company derives revenue through sales of its products.

Vivos Inc

<p>FGI Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FGI#NASDAQ">FGI</a>) is preparing to release its quarterly earnings on Monday, 2024-11-11. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect FGI Industries to report an <strong>earnings per share</strong> (EPS) of $0.03.</p>
<p>Anticipation surrounds FGI Industries's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.</p>
<p>New investors should understand that while earnings performance is important, market reactions are often driven by guidance.</p>
<h3>Earnings History Snapshot</h3>
<p>Last quarter the company missed EPS by $0.02, which was followed by a 3.83% increase in the share price the next day.</p>
<p>Here's a look at FGI Industries's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.03</td>
<td>-0.02</td>
<td>0.07</td>
<td>0.13</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.01</td>
<td>-0.05</td>
<td>0.06</td>
<td>0.05</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>4.0%</td>
<td>-10.0%</td>
<td>8.0%</td>
<td>2.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731085281_0_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of FGI Industries were trading at $0.93 as of November 07. Over the last 52-week period, shares are down 38.67%.  Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/FGI/earnings"><strong>To track all earnings releases for FGI Industries visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Earnings

What to Expect from FGI Industries's Earnings

<p>Ispire Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISPR#NASDAQ">ISPR</a>) is preparing to release its quarterly earnings on Monday, 2024-11-11. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect Ispire Technology to report an <strong>earnings per share</strong> (EPS) of $-0.05.</p>
<p>Investors in Ispire Technology are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Performance in Previous Earnings</h3>
<p>In the previous earnings release, the company beat EPS by $0.06, leading to a 0.0% drop in the share price the following trading session.</p>
<p>Here's a look at Ispire Technology's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.09</td>
<td>0.02</td>
<td>0.01</td>
<td></td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.03</td>
<td>-0.11</td>
<td>-0.07</td>
<td>-0.04</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>2.0%</td>
<td>6.0%</td>
<td>-10.0%</td>
<td>-16.0%</td>
</tr>
</tbody>
</table>
</p>
<h3>Ispire Technology Share Price Analysis</h3>
<p>Shares of Ispire Technology were trading at $6.18 as of November 07. Over the last 52-week period, shares are down 43.24%.  Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. </p>
<h3>Analysts' Perspectives on Ispire Technology</h3>
<p>For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Ispire Technology.</p>
<p>Analysts have given Ispire Technology a total of 1 ratings, with the consensus rating being Buy. The average one-year price target is $12.5, indicating a potential 102.27% upside.</p>
<h3>Analyzing Ratings Among Peers</h3>
<p>This comparison focuses on the analyst ratings and average 1-year price targets of  and Turning Point Brands, three major players in the industry, shedding light on their relative performance expectations and market positioning.</p>
<ul>
<li>The prevailing sentiment among analysts is an Buy trajectory for Turning Point Brands, with an average 1-year price target of $50.0, implying a potential 709.06% upside.</li>
</ul>
<h3>Peer Analysis Summary</h3>
<p>Within the peer analysis summary, vital metrics for  and Turning Point Brands are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ispire Technology</td>
<td>Buy</td>
<td>14.45%</td>
<td>$10.56M</td>
<td>-9.76%</td>
</tr>
<tr>
<td>Turning Point Brands</td>
<td>Buy</td>
<td>2.76%</td>
<td>$53.84M</td>
<td>7.81%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Ispire Technology ranks higher in Revenue Growth compared to its peers. However, it lags behind in Gross Profit and Return on Equity. Overall, it falls in the middle among its peers based on the provided metrics.</p>
<h3>Delving into Ispire Technology's Background</h3>
<p>Ispire Technology Inc is engaged in the research and development, design, commercialization, sales, marketing, and distribution of branded e-cigarettes and cannabis vaping products. The company sells its cannabis vaping in the United States, Europe, Canada, and South Africa.</p>
<h3>Understanding the Numbers: Ispire Technology's Finances</h3>
<p><strong>Market Capitalization Analysis:</strong> Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Ispire Technology showcased positive performance, achieving a revenue growth rate of <strong>14.45%</strong> as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Consumer Staples sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of <strong>-9.16%,</strong> the company may need to address challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Ispire Technology's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>-9.76%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Ispire Technology's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>-2.96%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Debt Management:</strong> Ispire Technology's debt-to-equity ratio is below the industry average. With a ratio of <b>0.1</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<p><a href="https://www.benzinga.com/quote/ISPR/earnings"><strong>To track all earnings releases for Ispire Technology visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


ISPR

A Look Ahead: Ispire Technology's Earnings Forecast

<p>Wells Fargo  analyst Will Gaertner   maintains Under Armour (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UAA#NYSE">UAA</a>) with a Equal-Weight and raises the price target from $8 to $11.</p>


News

Price Target

Analyst Ratings

Wells Fargo Maintains Equal-Weight on Under Armour, Raises Price Target to $11

<p>The Hershey Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HSY#NYSE">HSY</a>) today announced it has acquired Sour Strips, a fast-growing sour candy brand with a powerful social media presence. Sour Strips' "sour candy that doesn't suck" enhances Hershey's presence in the category and expands its reach to new consumers for more snacking occasions.</p>


Hershey Expands Sweets Portfolio With Acquisition Of Sour Strips; No Terms Disclosed

<p>Across the recent three months, 12 analysts have shared their insights on Carlyle Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CG#NASDAQ">CG</a>), expressing a variety of opinions spanning from bullish to bearish.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for Carlyle Group, revealing an average target of $53.5, a high estimate of $78.00, and a low estimate of $42.00. This current average has increased by 7.86% from the previous average price target of $49.60. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731085249_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive Carlyle Group. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kyle Voigt</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$55.00</td>
<td>$51.00</td>
</tr>
<tr>
<td>Kenneth Worthington</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$50.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>Brent Dilts</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$54.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Chris Kotowski</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$78.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Glenn Schorr</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$47.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Michael Cyprys</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$50.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Devin Ryan</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$60.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Michael Brown</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$48.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$50.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Michael Brown</td>
<td>Wells Fargo</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$42.00</td>
<td>-</td>
</tr>
<tr>
<td>Nicholas Watts</td>
<td>Redburn Atlantic</td>
<td>Announces</td>
<td>Buy</td>
<td>$55.00</td>
<td>-</td>
</tr>
<tr>
<td>Brian Bedell</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Buy</td>
<td>$53.00</td>
<td>$55.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Carlyle Group. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Carlyle Group compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of Carlyle Group's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Capture valuable insights into Carlyle Group's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/CG/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Carlyle Group analyst ratings.</strong></a></p>
<h2>Discovering Carlyle Group: A Closer Look</h2>
<p>The Carlyle Group is one of the world's largest alternative-asset managers, with $434.6 billion in total AUM, including $307.3 billion in fee-earning AUM, at the end of June 2024. The company has three core business segments: private equity, which includes private equity, real estate, infrastructure, and natural resources funds (accounting for 34% of fee-earning AUM and 58% of base management fees during 2023), global credit (51% and 27%) and investment solutions (15% and 15%). The firm primarily serves institutional investors and high-net-worth individuals. Carlyle operates through 29 offices across five continents, serving more than 2,900 active carry fund investors from 88 countries.</p>
<h3>Breaking Down Carlyle Group's Financial Performance</h3>
<p><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Carlyle Group's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of <strong>68.82%</strong>. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Financials sector, the company excelled with a growth rate higher than the average among peers.</p>
<p><strong>Net Margin:</strong> Carlyle Group's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of <strong>20.08%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Carlyle Group's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>2.93%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>0.69%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of <strong>2.1</strong>, caution is advised due to increased financial risk.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Scoreboard: 12 Ratings For Carlyle Group

<p>Roth MKM  analyst Jason Wittes   reiterates Orthofix Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OFIX#NASDAQ">OFIX</a>) with a Buy and raises the price target from $20 to $22.</p>


Reiteration

OFIX

Roth MKM Reiterates Buy on Orthofix Medical, Raises Price Target to $22

<p>Across the recent three months, 11 analysts have shared their insights on Arcellx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACLX#NASDAQ">ACLX</a>), expressing a variety of opinions spanning from bullish to bearish.</p>
<p>The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">8</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">7</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $104.73, a high estimate of $122.00, and a low estimate of $95.00. Witnessing a positive shift, the current average has risen by 21.27% from the previous average price target of $86.36.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731085243_0_0.png" alt="price target chart" /></p>
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive Arcellx. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biren Amin</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$115.00</td>
<td>$91.00</td>
</tr>
<tr>
<td>Gil Blum</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$105.00</td>
<td>$96.00</td>
</tr>
<tr>
<td>Judah Frommer</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$106.00</td>
<td>$81.00</td>
</tr>
<tr>
<td>Jason Gerberry</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$100.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Jack Allen</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$106.00</td>
<td>$77.00</td>
</tr>
<tr>
<td>Emily Bodnar</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$95.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Gil Blum</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$96.00</td>
<td>$96.00</td>
</tr>
<tr>
<td>Gil Blum</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$96.00</td>
<td>$96.00</td>
</tr>
<tr>
<td>Gil Blum</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$96.00</td>
<td>$81.00</td>
</tr>
<tr>
<td>Benjamin Burnett</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$122.00</td>
<td>$83.00</td>
</tr>
<tr>
<td>John Newman</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$115.00</td>
<td>$85.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Arcellx. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Arcellx compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts provide insights into price targets, offering estimates for the future value of Arcellx's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Arcellx's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/ACLX/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Arcellx analyst ratings.</strong></a></p>
<h2>All You Need to Know About Arcellx</h2>
<p>Arcellx Inc is a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases.</p>
<h3>Arcellx: A Financial Overview</h3>
<p><strong>Market Capitalization Analysis:</strong> With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Arcellx showcased positive performance, achieving a revenue growth rate of <strong>91.47%</strong> as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Arcellx's net margin excels beyond industry benchmarks, reaching <strong>-99.34%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>-5.53%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>-3.59%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.15</strong>.</p>
<h2>Analyst Ratings: What Are They?</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


ACLX

Analyst Expectations For Arcellx's Future

<p>Analysts' ratings for US Foods Hldg (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USFD#NYSE">USFD</a>) over the last quarter vary from bullish to bearish, as provided by 6 analysts.</p>
<p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $69.5, a high estimate of $75.00, and a low estimate of $60.00. This upward trend is apparent, with the current average reflecting a 8.59% increase from the previous average price target of $64.00.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731085235_0.png" alt="price target chart" /></p>
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
<p>The perception of US Foods Hldg by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>John Ivankoe</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$69.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>Jake Bartlett</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$74.00</td>
<td>$66.00</td>
</tr>
<tr>
<td>Alexander Slagle</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$71.00</td>
<td>$66.00</td>
</tr>
<tr>
<td>Edward Kelly</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$75.00</td>
<td>$66.00</td>
</tr>
<tr>
<td>John Ivankoe</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$68.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>John Ivankoe</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$60.00</td>
<td>$58.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to US Foods Hldg. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of US Foods Hldg compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of US Foods Hldg's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>For valuable insights into US Foods Hldg's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/USFD/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on US Foods Hldg analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind US Foods Hldg</h2>
<p>US Foods Holding Corp is the U.S. food service distributor. us Foods distributes food and nonfood products to the healthcare and hospitality industries, restaurants, and education, government facilities, and grocers. In addition to its delivery business, the firm has 80 cash-and- carry stores under the Chef'Store banner. The company generates majority of the revenue from Meats and seafood products.</p>
<h3>Financial Milestones: US Foods Hldg's Journey</h3>
<p><strong>Market Capitalization Analysis:</strong> With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.</p>
<p><strong>Revenue Growth:</strong> US Foods Hldg's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of <strong>7.72%</strong>. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Consumer Staples sector.</p>
<p><strong>Net Margin:</strong> US Foods Hldg's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>2.04%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> US Foods Hldg's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of <strong>4.03%,</strong> the company may encounter challenges in delivering satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> US Foods Hldg's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>1.46%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.98</strong>, US Foods Hldg adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


USFD

Forecasting The Future: 6 Analyst Projections For US Foods Hldg

<p>In the preceding three months, 4 analysts have released ratings for Akamai Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKAM#NASDAQ">AKAM</a>), presenting a wide array of perspectives from bullish to bearish.</p>
<p>The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets, analyzed by analysts, offer insights with an average target of $118.0, a high estimate of $140.00, and a low estimate of $100.00. Surpassing the previous average price target of $117.50, the current average has increased by 0.43%.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731085226_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>A clear picture of Akamai Techs's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patrick Colville</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Outperform</td>
<td>$112.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Ivan Feinseth</td>
<td>Tigress Financial</td>
<td>Maintains</td>
<td>Strong Buy</td>
<td>$140.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Rishi Jaluria</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$100.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Rudy Kessinger</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Buy</td>
<td>$120.00</td>
<td>$115.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Akamai Techs. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Akamai Techs compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of Akamai Techs's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Akamai Techs's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/AKAM/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Akamai Techs analyst ratings.</strong></a></p>
<h2>Get to Know Akamai Techs Better</h2>
<p>Akamai operates a content delivery network, which entails locating servers at the edges of networks so its customers, which store content on Akamai servers, can reach their own customers faster, more securely, and with better quality. Akamai has over 325,000 servers distributed over 4,100 points of presence in more than 1,000 cities worldwide. The firm also offers security and cloud computing for its customers, and those businesses have grown to be bigger than the legacy CDN.</p>
<h3>Financial Milestones: Akamai Techs's Journey</h3>
<p><strong>Market Capitalization:</strong> Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.</p>
<p><strong>Revenue Growth:</strong> Akamai Techs displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately <strong>4.69%</strong>. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Information Technology sector.</p>
<p><strong>Net Margin:</strong> Akamai Techs's net margin is impressive, surpassing industry averages. With a net margin of <strong>13.44%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>2.81%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Akamai Techs's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>1.32%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.97</strong>.</p>
<h2>Analyst Ratings: What Are They?</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


AKAM

Unveiling 4 Analyst Insights On Akamai Techs

<p>Analysts' ratings for Genmab (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GMAB#NASDAQ">GMAB</a>) over the last quarter vary from bullish to bearish, as provided by 10 analysts.</p>
<p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">7</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>In the assessment of 12-month price targets, analysts unveil insights for Genmab, presenting an average target of $46.0, a high estimate of $50.00, and a low estimate of $31.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 3.73%. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731085216_0.png" alt="price target chart" /></p>
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
<p>The standing of Genmab among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Etzer Darout</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$48.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$50.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$50.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$50.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$50.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Vikram Purohit</td>
<td>Morgan Stanley</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$31.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Asthika Goonewardene</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$50.00</td>
<td>$53.00</td>
</tr>
<tr>
<td>Vikram Purohit</td>
<td>Morgan Stanley</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$31.00</td>
<td>-</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$50.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$50.00</td>
<td>$50.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Genmab. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Genmab compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Genmab's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Genmab's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/GMAB/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Genmab analyst ratings.</strong></a></p>
<h2>Delving into Genmab's Background</h2>
<p>Genmab AS is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson &amp; Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson &amp; Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.</p>
<h3>Breaking Down Genmab's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Genmab's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately <strong>17.57%</strong>. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Genmab's net margin excels beyond industry benchmarks, reaching <strong>22.85%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> Genmab's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>4.03%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Genmab's ROA excels beyond industry benchmarks, reaching <strong>3.23%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Genmab's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.03</strong>.</p>
<h2>Analyst Ratings: What Are They?</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


GMAB

A Closer Look at 10 Analyst Recommendations For Genmab

<p>Providing a diverse range of perspectives from bullish to bearish, 5 analysts have published ratings on Genpact (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/G#NYSE">G</a>) in the last three months.</p>
<p>The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have recently evaluated Genpact and provided 12-month price targets. The average target is $43.4, accompanied by a high estimate of $48.00 and a low estimate of $40.00. Witnessing a positive shift, the current average has risen by 14.21% from the previous average price target of $38.00.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731085208_0.png" alt="price target chart" /></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<p>The analysis of recent analyst actions sheds light on the perception of Genpact by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Koning</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$48.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>David Koning</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$44.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Surinder Thind</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Hold</td>
<td>$40.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Tien-Tsin Huang</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$43.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Keith Bachman</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$42.00</td>
<td>$38.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Genpact. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Genpact compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of Genpact's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Capture valuable insights into Genpact's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/G/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Genpact analyst ratings.</strong></a></p>
<h2>All You Need to Know About Genpact</h2>
<p>Genpact Ltd is a provider of business process management services. Clients are industry verticals and operate in banking and financial services, insurance, capital markets, consumer product goods, life sciences, infrastructure, manufacturing and services, healthcare, and high-tech. Genpact's services include aftermarket, direct procurement, risk and compliance, human resources, IT, industrial solutions, collections, finance and accounting, and media services. Genpact's end market by revenue is India. It is a General Electric spin-off, which is still a large source of revenue for Genpact.</p>
<h3>Breaking Down Genpact's Financial Performance</h3>
<p><strong>Market Capitalization:</strong> Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Genpact's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>6.39%</strong> as of 30 June, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Industrials sector.</p>
<p><strong>Net Margin:</strong> Genpact's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of <strong>10.37%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Genpact's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of <strong>5.26%,</strong> the company may encounter challenges in delivering satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Genpact's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>2.46%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Debt Management:</strong> Genpact's debt-to-equity ratio is below the industry average. With a ratio of <b>0.8</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


5 Analysts Assess Genpact: What You Need To Know

<p>Wells Fargo  analyst Ike Boruchow   maintains Canada Goose Hldgs (TSX:<a class="ticker" href="https://www.benzinga.com/stock/GOOS#TSX">GOOS</a>) with a Underweight and lowers the price target from C$12 to C$11.</p>


TSX:GOOS

Wells Fargo Maintains Underweight on Canada Goose Hldgs, Lowers Price Target to C$11

<p>Shares of <strong>Pinterest Inc </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PINS#NYSE">PINS</a>) tumbled in early trading on Friday, after the company reported <a href="https://www.benzinga.com/news/earnings/24/11/41827920/pinterest-q3-earnings-revenue-beat-eps-miss-soft-guidance-ai-investments-paying-off-and-more">downbeat third-quarter earnings</a>.</p>
<p>The company reported its results amid an <a href="https://www.benzinga.com/earnings">exciting earnings season</a>. Here are some key analyst takeaways.</p>
<ul>
<li>Piper Sandler <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5981fdcbc1f558000155e858/thomas-champion">analyst Thomas Champion</a> maintained an Overweight rating and reduced the price target from $45 to $41.</li>
<li>JPMorgan <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/591479b8290fa7000138e4b4/doug-anmuth">analyst Doug Anmuth</a> reiterated a Neutral rating and cut the price target from $38 to $35.</li>
<li>BofA Securities <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58d94a96b85e930001fd9dd6/justin-post">analyst Justin Post</a> reaffirmed a Buy rating and slashed the price target from $45 to $39.</li>
<li>Wedbush <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58459503ee7bf6000154d075/scott-devitt">analyst Scott Devitt</a> maintained a Neutral rating, but lifted the price target from $37 to $38.</li>
<li>Roth Capital Partners <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5e3c22772d37ce00019ceb1f/rohit-kulkarni">analyst Rohit Kulkarni</a> reiterated a Neutral rating and trimmed the price target from $39 to $33.</li>
<li>Raymond James <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/593aad8285b07a00019621a5/josh-beck">analyst Josh Beck</a> reaffirmed an Outperform rating and cut the price target from $40 to $34.</li>
<li>Oppenheimer <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5846f34dee7bf6000154d139/jason-helfstein">analyst Jason Helfstein</a> maintained an Outperform rating and revised the price from $45 to $40.</li>
<li>Benchmark <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5e3ab1ed2d37ce00019ca05b/mark-zgutowicz">analyst Mark Zgutowicz</a> reiterated a Hold rating on the stock.</li>
</ul>
<p><strong>Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a></strong>.</p>
<p><strong>Piper Sandler</strong>: Pinterest reported third-quarter revenues of $898 million, up 18% year-on-year and around 1% higher than Street expectations, Champion said in a note. He added, however, that the fourth-quarter guidance of 15%-17% represents another deceleration.</p>
<p>While EBITDA of $242 million was above estimates, the company's year-on-year margin expansion is slowing, the analyst stated. "Users improved across all geographies, with y/y growth decelerating slightly on a 1% tougher comp," he further wrote.</p>
<p><strong>JPMorgan</strong>: Pinterest's stock declined in the after-hours trading session as the company's revenue growth guidance "fell shy of investor expectations," Anmuth said. Although Pinterest indicated that macro trends "are mostly stable," but persistent Food &amp; Beverage pressure could weigh on revenue growth into the holiday season, he added.</p>
<p>Pinterest launched its Performance+ AI suite, "which provides AI/automation tools across bidding, budgeting, &amp; targeting," which is driving higher cost per action (CPA) and return on ad spend (ROAS), the analyst stated. "We remain Neutral-rated &amp; look for stronger growth &amp; execution to become more constructive," he further wrote.</p>
<p><strong>BofA Securities</strong>: Although Pinterest's third-quarter revenues were broadly in-line with Street expectations, the performance was disappointing, "given beats at peers," Post said. "While Pinterest&#8217;s 18% growth was likely above industry, food and beverage category weakness was likely a 4pt headwind, bigger than peers," he added.</p>
<p>The company's fourth-quarter revenue guidance of $1,125-$1,145 million represents 15%-17% year-on-year growth but came in slightly below consensus and the high end of the range "suggests 1pts decel. on 1pt tougher y/y comp," the analyst stated. While management expects contribution from AI tools to "start to help" in the first half of 2025, the first-quarter revenue comp "is very difficult," he further wrote.</p>
<p><strong>Wedbush</strong>: Pinterest reported "healthy" third-quarter results and provided guidance for the fourth quarter that was broadly in-line with estimates, Devitt said.</p>
<p>Investors remained concerned about the company's ability to sustain high-teens growth in 2025 against tougher comps, the impact of rising ad loads on user engagement metrics, and continued headwinds from weakness in the food &amp; beverage category, the analyst stated. "We think Pinterest is likely to achieve revenue growth closer to the range of its longer-term target (mid-to-high teens CAGR over the next 3-5 years)," he further wrote.</p>
<p><strong>Roth Capital Partners</strong>: Pinterest reported a small beat on revenues but missed EBITDA expectations, Kulkarni said. "Mgmt. seemed upbeat about growing bottom-of-funnel ad revs, AI-driven content recommendation, and Performance+ adoption since Oct 1st general availability," he added.</p>
<p>In in search results, average ad relevance has more than doubled over the past two years, and search accounts for two-thirds of Pinterest&#8217;s business, the analyst stated. "Pinterest is leveraging AI to flex up ad load during moments of high intent, allowing ad load and engagement to grow in tandem," he further wrote.</p>
<p><strong>Raymond James</strong>: Pinterest's performance in the third quarter showed "signs of progress against key initiatives" related to artificial intelligent and deep learning as well as improving engagement, Beck said. He added, however, that the visibility into shopping ad gains and recovery in the Food &amp; Beverage category remain "somewhat limited."</p>
<p>The company's fourth-quarter guidance fell short of expectations and was below 2023 seasonality, possibly due to "a full quarter of ongoing F&amp;B headwinds," the analyst stated. "We had previewed a mixed setup for PINS flagging a decel in F&amp;B sales projections, but didn't necessarily expect the headwinds (trade-down, promos, inflation) to persist," he further wrote.</p>
<p><strong>Oppenheimer</strong>: While growth in Pinterest's monthly average users (MAUs) in North America remained flat at 3%, that in Europe decelerated to 9% from 10% in the second quarter, Helfstein said. This was the fourth consecutive quarter where outbound clicks to advertisers grew by 2x year-on-year, he added.</p>
<p>Advertisers using Performance+ (AI product suite) are seeing 20% average improvement in cost per action, the analyst stated. He expects revenue growth to decelerate to 10% year-over-year in the first quarter of 2025, but to ramp through the year.</p>
<p><strong>Benchmark</strong>: Management indicated continued weakness in the Food and Beverage vertical and "suggested a more deliberate rollout and subsequent uptake of Performance+ beginning in ‘25E," Zgutowicz said. Pinterest also expects new budget spend to be limited for products like Performance+ during the holiday period, he added.</p>
<p>"Continued expanding 3P ad supply dynamics kept impression growth (+41% y/y) elevated and pricing (-17% y/y) decelerating in 3Q, a trendline we expect to continue the next few quarters," the analyst wrote. Although Pinterest's MAU continues to increase, excessive ad load could soon begin negatively impacting engagement, he further stated.</p>
<p><strong>Price Action:</strong> Shares of Pinterest had declined by 16.27% to $28.62 at the time of publication on Friday.</p>
<p><strong>Read More: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/news/earnings/24/10/41311149/pinterest-time-to-jump-onboard-for-long-term-gains">Pinterest: Time to Jump Onboard for Long-Term Gains?</a></strong></li>
</ul>
<p><em>Image: Shutterstock</em></p>


Analyst Color

Earnings Beats

Movers

Trading Ideas

PINS

Pinterest Reports Healthy Q3, Q4 Guidance Disappoints: 6 Analysts Cut Forecasts — Will AI Tools 'Start To Help' In 2025?

<p>HC Wainwright &amp; Co.  analyst Ed Arce   reiterates Pliant Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRX#NASDAQ">PLRX</a>) with a Buy and maintains $38 price target.</p>


PLRX

HC Wainwright & Co. Reiterates Buy on Pliant Therapeutics, Maintains $38 Price Target

<p><strong>Super Micro Computer, Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) faces possible delisting after its auditor <strong>Ernst &amp; Young </strong>resigned amid allegations of accounting irregularities and claims of potential export control violations. Adding to Super Micro's woes, the company could face an early repayment on up to $1.725 billion of <a href="https://www.benzinga.com/news/24/02/37287458/whats-going-on-with-super-micro-computer-stock">its bonds if delisted.&nbsp;</a></p>
<p><strong>The Details:</strong> According to the bonds<a href="https://ir.supermicro.com/news/news-details/2024/Supermicro-Announces-Pricing-of-Private-Offering-of-1.5-Billion-of-Convertible-Senior-Notes-Due-2029/default.aspx"> documentation</a>, holders of Super Micro's $1.725 billion convertible notes due March 2029 have the option of getting their money back early if the shares are delisted from Nasdaq and are not immediately re-listed, re-traded or re-quoted. </p>
<p>Super Micro faces a potential delisting from the Nasdaq if it does not submit its annual report to the SEC by mid-November.&nbsp;</p>
<p><strong>Read Next: </strong><a href="https://www.benzinga.com/news/24/11/41781921/what-does-trumps-victory-mean-for-ev-giant-tesla-and-the-big-3-automakers"><strong>What Does Trump&#8217;s Victory Mean For EV Giant Tesla And The Big 3 Automakers?</strong></a></p>
<p>However, the company said on its first-quarter earnings call Tuesday that it is working on a compliance plan, which could extend the deadline to submit audited financials to February 2025.&nbsp;</p>
<p>"We&#8217;re diligently looking to replace the auditor as quickly as possible. And we will be filing a plan with Nasdaq and indeed regarding an extension&#8230; but that&#8217;s all we have to say about that," said <strong>David Weigand</strong>, Super Micro's CFO. </p>
<p>An analyst also asked what happens with the company's bank debt and convertible debt if audited financials are not submitted within the prescribed time.&nbsp;</p>
<p>"We have long-term and good relationships with the banks. And so as necessary, we will file extensions, yes, or get waivers. As I mentioned earlier, we&#8217;re not concerned about the company&#8217;s ability to access the capital markets," Weigand said. </p>
<p>According to Super Micro's<a href="https://www.benzinga.com/news/earnings/24/11/41759924/super-micro-computer-stock-sinks-on-preliminary-q1-results-q2-guidance-business-update"> first-quarter report</a>, the company had about $2.1 billion in cash or equivalents at the end of September. Wedbush analyst <strong>Matt Bryson</strong> said the company's large cash reserve gives it <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41780680/super-micro-analysts-need-more-clarity-on-auditor-resignation-await-10-k-filing-man">more options</a> if it needs to restructure its debt.&nbsp;</p>
<p>Super Micro's delisting and resulting payment on its large sum of debt remains "certainly a risk," Bryson said in an interview, according to Bloomberg.&nbsp;</p>
<p><strong>SMCI Price Action:</strong> According to data from Benzinga Pro, Super Micro Computer shares are down 3.5% at $24.57 at the time of publication Friday. </p>
<p><strong>Read More:&nbsp;</strong></p>
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/11/41822473/trumps-potential-health-czar-robert-f-kennedy-jr-rattles-vaccine-stocks-shoot-first-reaction"><strong>Trump&#8217;s Potential &#8216;Health Czar&#8217; Robert F. Kennedy Jr. Rattles Vaccine Stocks: &#8216;Shoot First Reaction&#8217;</strong></a></li>
</ul>
<p><em>Photo: Shutterstock</em></p>


Topics

SMCI

Super Micro Delisting Risk Puts $1.7 Billion Bond Repayment On The Line

Economics

TMUS

Live On CNBC, T-Mobile CEO Mike Sievert Discusses President-Elect Trump Policy, Regulation, Broadband Access, Growth Of Business, OpenAI Partnership And AI Ambitions

<p>HC Wainwright &amp; Co.  analyst Robert Burns   reiterates Allogene Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALLO#NASDAQ">ALLO</a>) with a Buy and maintains $9 price target.</p>


ALLO

HC Wainwright & Co. Reiterates Buy on Allogene Therapeutics, Maintains $9 Price Target

<p>Maxim Group  analyst Jason McCarthy   downgrades Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) from Buy to Hold.</p>


Downgrades

GILD

Maxim Group Downgrades Gilead Sciences to Hold

<p>Benchmark  analyst David Williams   maintains MACOM Technology Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTSI#NASDAQ">MTSI</a>) with a Buy and raises the price target from $120 to $160.</p>


MTSI

Benchmark Maintains Buy on MACOM Technology Solns, Raises Price Target to $160

<p><a href="https://www.nytimes.com/2024/11/08/business/economy/house-committee-china-semiconductor-manufacturing.html" title="https://www.nytimes.com/2024/11/08/business/economy/house-committee-china-semiconductor-manufacturing.html">https://www.nytimes.com/2024/11/08/business/economy/house-committee-china-semiconductor-manufacturing.html</a></p>


AMAT

ASML

KLAC

LRCX

Reported Earlier, U.S. Lawmakers Seek Details On China Sales From Top Semiconductor Equipment Makers, Including KLA, Applied Materials, Lam Research, Tokyo Electron, And ASML

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>I cannot stress enough how risky OTC stocks or securities traded over the counter really are. For one thing, just the name OTC should ring some alarm bells. This designation means that these securities don&rsquo;t trade on exchanges like the <strong>New York Stock Exchange</strong> or the <strong>Nasdaq</strong>. Instead, they trade via broker-dealer networks. And not all stock platforms support what&rsquo;s otherwise known as the pink sheets.</p>



<p>Second, many investors are shocked to discover the administrative costs tied to OTC stocks. Yes, many of these securities are &ldquo;cheap,&rdquo; trading hands at unit prices well below a buck. However, that doesn&rsquo;t mean that it&rsquo;s cheap to <em>you</em>. Wide bid-ask spreads may mean that your holdings may have to rise significantly higher to be net profitable. Also, even if you are profitable, low trading volume could mean a long time to find a buyer.</p>



<p>At the same time, OTC stocks or otherwise highly speculative shares can fly higher. Some <a href="https://www.gobankingrates.com/investing/stocks/most-successful-penny-stocks-ever/">examples</a> include the following:</p>



<ul><li><strong>Monster Beverage</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/mnst-stock-quote/"><strong>MNST</strong></a>): In 1997, you could have had MNST for just two cents.</li>



<li><strong>Apple</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/aapl-stock-quote/"><strong>AAPL</strong></a>): On a split-adjusted basis, you could have bought AAPL for 10 cents in December 1980.</li>



<li><strong>Advanced Micro Devices</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/amd-stock-quote/"><strong>AMD</strong></a>): Back in June 2015, AMD traded for below $2.</li>
</ul><p>Of course, there are way more failures than successes. But if you want to go for gold, below are the OTC stocks to consider.</p>



<h2>Tencent (TCEHY)</h2>


<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/08/tcehy-stock-3-300x169.jpg" alt="Tencent (TCEHY) sign on Tencent headquarters in Shenzhen, China."><div>Source: StreetVJ / Shutterstock.com</div></div>


<p>A Chinese multinational technology conglomerate, <strong>Tencent</strong> (OTCMKTS:<a href="https://investorplace.com/stock-quotes/tcehy-stock-quote/"><strong>TCEHY</strong></a>) has had a rough outing in 2023. Mainly, that&rsquo;s due to the challenging circumstances surrounding the Chinese economy. And if a <em>CNN</em> report proves correct, 2024 <a href="https://www.cnn.com/2023/12/27/economy/china-economy-challenges-2024-intl-hnk/index.html">could be an even rougher outing</a>. Still, Tencent&rsquo;s <a href="https://www.reuters.com/technology/tencent-reveals-most-ambitious-game-yet-consoles-amid-global-expansion-2023-12-08/">expansionary ambitions</a> reach beyond its home nation. With eyes on Japan, South Korea, Southeast Asia, and <a href="https://www.prnewswire.com/apac/news-releases/tencent-cloud-highlights-collaborative-global-expansion-with-digital-ecological-partners-at-tencent-cloud-digital-ecosystem-summit-2023-global-connect-session-301921841.html#:~:text=Fred%20Sun%2C%20General%20Manager%20of,East%2C%20providing%20solutions%20for%20various">several other international regions</a>, Tencent could be interesting for speculators.</p>



<p>To be sure, with a market capitalization of around $337.5 billion, TCEHY doesn&rsquo;t exactly rate as one of the typical OTC stocks. However, it&rsquo;s a great confidence booster because it&rsquo;s in some ways the best of both worlds: offering tremendous upside potential while also being a technology stalwart in its home nation.</p>



<p>Analysts rate shares a <a href="https://www.tipranks.com/stocks/tcehy">consensus moderate buy</a> with a $49.56 average price target. That implies an upside potential of over 40%. What&rsquo;s more, the high-side target hits $61.13, possibly delivering growth of over 73%. If that wasn&rsquo;t enough to whet your appetite, shares <a href="https://www.gurufocus.com/stock/TCEHY/summary?search=tcehy">trade at only 13.06X forward earnings</a>, below the interactive media sector&rsquo;s median value of 21.19X.</p>



<h2>BYD (BYDDF)</h2>


<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/09/byddf-stock-1-300x169.jpg" alt="A close-up view of the power supply plugged into a vehicle from BYD Company (BYDDY)."><div>Source: J. Lekavicius / Shutterstock.com</div></div>


<p>Moving on to another Chinese company, <strong>BYD</strong> (OTCMKTS:<a href="https://investorplace.com/stock-quotes/byddf-stock-quote/"><strong>BYDDF</strong></a>) presents a unique proposition. First, it&rsquo;s a major automotive enterprise specializing in electric vehicles, yet it technically ranks among the OTC stocks. Second, Warren Buffett &ndash; who is best known for investing in reliable blue chips &ndash; <a href="https://www.cnbc.com/berkshire-hathaway-portfolio/">owns BYD</a> via <strong>Berkshire Hathaway</strong> (NYSE:<span><a href="https://investorplace.com/stock-quotes/brk-b-stock-quote/"><strong>BRK-B</strong></a></span>). To be fair, Buffett has been <a href="https://apnews.com/article/berkshire-hathaway-warren-buffett-byd-397410cefd128f283c5efcc7cf90c1fa">reducing his exposure</a> but he still owns a sizable amount.</p>



<p>Despite the seemingly contradictory tone, investors may want to consider adding BYDDF to their portfolio. Yeah, it&rsquo;s one of the OTC stocks and yes, the Chinese economy looks rather putrid if I&rsquo;m being honest. However, with EVs becoming increasingly commoditized, guess who&rsquo;s going to win that battle? There&rsquo;s just no way that western nations can compete with their higher labor costs.</p>



<p>Also, investors should consider another element: demand. European politicians may want to reduce the flood of Chinese EVs. But their constituents? They love &lsquo;em. So do analysts, who rate BYDDF a <a href="https://www.tipranks.com/stocks/byddf/forecast">consensus strong buy</a> with a $36.03 price target. That implies 63% upside potential.</p>



<h2>Xiaomi (XIACF)</h2>


<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2023/05/electric-vehicle-charger1600-300x169.png" alt="Power supply connect to electric vehicle for charge to the battery. Charging technology industry transport which are the futuristic of the Automobile. EV fuel Plug in hybrid car."><div>Source: buffaloboy / Shutterstock.com</div></div>


<p>Yet one more Chinese company to discuss and then we&rsquo;ll get into the really wild OTC stocks. A designer and manufacturer of consumer electronics and related software, <strong>Xiaomi</strong> (OTCMKTS:<a href="https://investorplace.com/stock-quotes/xiacf-stock-quote/"><strong>XIACF</strong></a>) is a cynical play. For example, beyond its consumer electronics business, it&rsquo;s also involved in the EV space. Recently, the company <a href="https://www.cnbc.com/2023/12/28/chinas-xiaomi-unveils-first-ev-in-bid-to-compete-with-porsche-tesla.html">launched its first electric-powered vehicle</a>, which might have caught the eyes of some lawyers.</p>



<p>I&rsquo;m joking there, but seriously, the <a href="https://www.mi.com/global/discover/article?id=3095&amp;ref=upstract.com">Xiaomi SU7</a> looks like it ripped off the design of a particular German brand. But if the consumers who love BYD offer any clues, the SU7 should be a hit. Apparently, it has the performance (<a href="https://www.topspeed.com/xiaomi-su7-ev-facts/#:~:text=Performance%20Specifications&amp;text=The%20SU7%20Max%20trim%20will,top%20speed%20of%20165%20mph.">up to 664 horsepower</a>) and the longevity to <a href="https://www.carscoops.com/2023/12/xiaomis-su7-will-outrun-a-taycan-and-outlast-a-tesla-model-s/">better the top players in the ecosystem</a>. And even if you didn&rsquo;t like the EV pivot, Xiaomi should win in consumer electronics.</p>



<p>Frankly, with smart devices becoming so commoditized, people may start looking to price more often than brand. If so, XIACF has a clear pathway to robust shareholder profits. Analysts agree, rating the stock a <a href="https://www.tipranks.com/stocks/xiacf/forecast">unanimous strong buy</a> with a $2.66 average price target.</p>



<h2>Quisitive Technology Solutions (QUISF)</h2>


<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/cloud1600d-300x169.jpg" alt=""><div>Source: Shutterstock</div></div>


<p>Okay, let&rsquo;s buckle up for some serious OTC stocks and by that, I mean high risk, high reward. First, <strong>Quisitive Technology Solutions</strong> (OTCMKTS:<a href="https://investorplace.com/stock-quotes/quisf-stock-quote/"><strong>QUISF</strong></a>) bills itself as a premier global <strong>Microsoft</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/msft-stock-quote/"><strong>MSFT</strong></a>) partner that harnesses its cloud platforms and complete technologies to generate transformational impact for midsize and enterprise-level customers. It&rsquo;s an intriguing idea because, at one point, shares closed at $1.54 on a weekly average basis.</p>



<p>Currently, QUISF trades hands at only 22 cents. And you should note that over the past 52 weeks, it lost more than 53% of its equity value. Further, according to the security&rsquo;s point-and-figure (P&amp;F) chart, it prints a double bottom breakdown. According to StockCharts.com&rsquo;s educational section, this pattern is a bearish signal. That said, the pattern should also be viewed in a <a href="https://school.stockcharts.com/doku.php?id=chart_analysis:pnf_charts:pnf_bearish_bd#:~:text=for%20price%20objectives.-,Double%20Bottom%20Breakdown,These%20patterns%20are%20not%20contradictory.">broader context</a> due to possible whipsaw effects.</p>



<p>And what is that context? Basically, the broader cloud computing market <a href="https://www.fortunebusinessinsights.com/cloud-computing-market-102697">could be worth $2.43 trillion</a> by 2030. Quisitive just needs to take a bite out of this market to potentially drive higher. Analysts seem to be on the same page, pegging the <a href="https://www.tipranks.com/stocks/quisf/forecast">average price target at 49 cents</a>.</p>



<h2>Peninsula Energy (PENMF)</h2>


<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/uranium1600-300x169.jpg" alt="periodic table concept with black cubes. uranium element is glowing. Uranium stocks"><div>Source: Shutterstock</div></div>


<p>As a fan of the uranium energy space, I perked up when I came across this opportunity hidden among OTC stocks. As a uranium extraction specialist, <strong>Peninsula Energy</strong> (OTCMKTS:<a href="https://investorplace.com/stock-quotes/penmf-stock-quote/"><strong>PENMF</strong></a>) addresses a critical supply shortage that recently sprouted. According to <em>The Wall Street Journal</em>, last month, <a href="https://www.wsj.com/finance/commodities-futures/uranium-prices-jump-to-16-year-high-on-supply-woes-analysis-05c7086f">uranium prices jumped to a 16-year high</a> after one of the world&rsquo;s largest producers &ndash; Kazakhstan&rsquo;s state-owned company <strong>Kazatomprom</strong> &ndash; warned of production target shortfalls.</p>



<p>With uranium supplies uncertain for the next two years, several uranium players have skyrocketed. One of the exceptions is PENMF. In the trailing one-year period, the security declined by 8%. That said, it is up 15% on a year-to-date basis but that&rsquo;s a modest performance compared to exchange-listed uranium specialists.</p>



<p>Still, as far as OTC stocks are concerned, Peninsula could be intriguing because of geopolitical considerations. Basically, it features 100% ownership of the Lance Project, which is one of the largest uranium projects in the U.S.</p>



<p>Better yet, analysts expect great things, pegging shares a moderate buy with a 17-cent target. That implies almost 85% upside potential, with the high-side target landing at 22 cents.</p>



<h2>Saturn Oil &amp; Gas (OILSF)</h2>


<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2023/03/oilandgasstocks1600-300x169.png" alt="Panorama of Oil and Gas central processing platform in twilight, offshore hard work occupation twenty four working hours. Best oil stocks to buy"><div>Source: Oil and Gas Photographer / Shutterstock.com</div></div>


<p>Based in Calgary, Alberta, Canada, <strong>Saturn Oil &amp; Gas</strong> (OTCMKTS:<a href="https://investorplace.com/stock-quotes/oilsf-stock-quote/"><strong>OILSF</strong></a>) is a resource company engaged in the business of acquisition, exploration and development of petroleum and natural gas resource despoits in Western Canada. Further, the company&rsquo;s current focus is to advance the exploration and development of its oil and gas properties in Alberta and Saskatchewan.</p>



<p>As an upstream player in the hydrocarbon space, Saturn might not seem particularly relevant. Late last year, many oil-producing nations <a href="https://www.cnn.com/2023/11/30/energy/saudi-arabia-extend-production-cut-opec/index.html">agreed to cut production in a bid to bolster prices</a>. However, that effort did not succeed. Also, <em>Reuters</em> recently reported that rising U.S. oil production has <a href="https://www.reuters.com/markets/commodities/rising-us-oil-production-frustrates-opec-cuts-kemp-2024-02-01/">frustrated the aforementioned oil producers</a>. So, it seems OILSF could be one of the losing OTC stocks.</p>



<p>However, the blowout <a href="https://finance.yahoo.com/news/january-jobs-report-us-economy-adds-353000-jobs-blowing-past-wall-street-expectations-133251408.html">January jobs report</a> suggests that we shouldn&rsquo;t quite give up on black gold just yet. More people with jobs should translate to more resource consumption. And to be blunt, renewable energy just won&rsquo;t be enough to feed the growing demand profile. Notably, Echelon Wealth Partners believes OILSF <a href="https://www.tipranks.com/stocks/oilsf/forecast">could hit $4.22 per share or 137% up</a>.</p>



<h2>Vivos (RDGL)</h2>


<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/07/medical-bills-1600-300x169.png" alt="Doctor or physician calculating a patients medical bills at a desk. Medical bills, health costs, health expenses."><div>Source: THICHA SATAPITANON / Shutterstock</div></div>


<p>Before discussing radiation oncology medical device firm <strong>Vivos</strong> (OTCMKTS:<a href="https://investorplace.com/stock-quotes/rdgl-stock-quote/"><strong>RDGL</strong></a>), it&rsquo;s important to disclose that I own RDGL stock. Please make a decision based on your own due diligence and a sober reflection of your risk tolerance. This is a security that has already lost almost 28% YTD and is likely subject to severe market turbulence.</p>



<p>With the caveats out of the way, Vivos is engaged in the development of its <a href="https://www.radiogel.com">yttrium-90-based brachytherapy device, RadioGel</a>, for the treatment of non-resectable tumors. According to Johns Hopkins Medicine, brachytherapy is a <a href="https://www.hopkinsmedicine.org/health/treatment-tests-and-therapies/brachytherapy">radiation treatment</a> that is given directly into the patient&rsquo;s body. Typically, the radiation is deployed using tiny devices such as wires, seeds, or rods filled with radioactive materials.</p>



<p>Where Vivos distinguishes itself is that RadioGel utilizes an injectable particle-gel, which delivers a very high local radiation dose. More broadly, RDGL entices speculators because the underlying industry is still in its early innings, <a href="https://www.grandviewresearch.com/industry-analysis/brachytherapy-devices-market">worth $907.76 million in 2022</a>.</p>



<p>As for a price target, it&rsquo;s difficult to say as no analyst currently covers RDGL. However, <a href="https://upperdeckoptions.com/2024/01/31/rdgl-stock-a-potential-sentiment-shift-in-2023/">based on my personal research</a>, I believe around 5 cents is the bottom.</p>



<p><strong><a href="https://investorplace.com/stock-types/penny-stocks/">Penny Stocks</a></strong></p>



<p><strong><em>On Penny Stocks and Low-Volume Stocks:</em></strong><em>&nbsp;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&nbsp;<a href="http://investorplace.com/">InvestorPlace.com</a>&rsquo;s writers disclose this fact and warn readers of the risks.</em></p>



<p><em>Read More:&nbsp;Penny Stocks &mdash;&nbsp;</em><a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/"><em>How to Profit Without Getting Scammed</em></a></p>



<p><em>On the date of publication, Josh Enomoto</em><em>&nbsp;held a LONG position in&nbsp;RDGL. </em><em>The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;</em><a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank"><em>Publishing Guidelines</em></a><em>.</em></p>
<div><p>A former senior business analyst for Sony Electronics, Josh Enomoto has helped broker major contracts with Fortune Global 500 companies. Over the past several years, he has delivered unique, critical insights for the investment markets, as well as various other industries including legal, construction management, and healthcare. Tweet him at @EnomotoMedia.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/07/venture-capitalist-predicts-this-chatgpt-announcement-will-shock-the-world/?cid=MKT744191&amp;eid=MKT766413">ChatGPT IPO Could Shock the World, Make This Move Before the Announcement</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
<p>The post <a href="https://investorplace.com/2024/02/high-risk-high-reward-7-otc-stocks-that-could-make-you-rich-this-year/">High-Risk, High-Reward: 7 OTC Stocks That Could Make You Rich This Year</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

High-Risk, High-Reward: 7 OTC Stocks That Could Make You Rich This Year

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>If you want millionaire-maker stocks, go consult Warren Buffett. The Oracle of Omaha has plenty of compelling ideas. However, if you want to reach millionaire status quickly, you&rsquo;re going to need to dial up the risk factor.</p>



<p>Here, the narrative is quite simple. If you want to give yourself a realistic possibility &ndash; note I didn&rsquo;t say probability &ndash; of winning big, you&rsquo;ve got to target extremely speculative market ideas. Usually, that means <a href="https://investorplace.com/stock-types/penny-stocks/">penny stocks</a> or shares that are priced so low they can benefit from the law of small numbers.</p>



<p>However, once the initial liftoff is achieved, the beneficiary enterprises need attractive businesses to keep the fire burning. Arguably, the below companies have exactly that &ndash; but you better be prepared for extreme volatility. On that note, take a look at these millionaire-maker stocks.</p>



<h2>Knightscope (KSCP)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/03/kscp-stock-300x169.png" alt="An image of a Knightscope, Inc. (KSCP) robot in a parking garage"><div>Source: Sundry Photography / Shutterstock.com</div></div><p>Billed as a security camera and robotics firm, <strong>Knightscope</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/kscp-stock-quote/"><strong>KSCP</strong></a>) designs, builds, and deploys robots called <a href="https://www.knightscope.com">Autonomous Data Robots</a>. This solution allows for the monitoring of people in malls, parking lots, neighborhoods, and other public areas. Fundamentally, the main positive catalyst for KSCP stock centers on security.</p>



<p>As a Californian, one news item caught my eye: the popular In-N-Out Burger will <a href="https://apnews.com/article/oakland-innout-burger-closing-crime-9cd8f43eb43fe781086b9e277eb0724d#:~:text=January%2026%2C%202024-,OAKLAND%2C%20Calif.,only%20restaurant%20in%20Oakland%2C%20California.">close its first location</a> in its 75-year history in Oakland. To the chagrin of residents, a wave of car break-ins, property damage, theft, and robberies affecting both customers and employees took their toll on the business. It&rsquo;s incidents like this multiplied at a scale that demonstrates the forward viability of KSCP as one of the millionaire-maker stocks.</p>



<p>To be sure, Knightscope carries significant risks, including <a href="https://www.gurufocus.com/stock/KSCP/analysis/warning-signs">several severe ones</a>, per investment data aggregator Gurufocus. Still, after a rough patch in getting the business moving, the company has printed encouraging <a href="https://www.gurufocus.com/stock/KSCP/financials">revenue growth</a> recently.</p>



<p><a href="https://www.businesswire.com/news/home/20240104703804/en/Ascendiant-Capital-Markets-Maintains-Buy-Rating-for-Knightscope-Raises-Per-Share-Price-Target-to-4.00">Ascendiant&rsquo;s Edward Woo believes shares can hit $4</a>. If so, we&rsquo;re talking upside potential of over 692%.</p>



<h2>Quantum Computing (QUBT)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/09/quantum-computing-3-300x169.jpg" alt="A concept image showing a quantum computer with a matrix background; quantum computing. leading quantum stocks, quantum computing stocks to buy"><div>Source: Shutterstock</div></div><p>I love companies that explain what they do just with their title. Here on this list of millionaire-maker stocks, we have <strong>Quantum Computing</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/qubt-stock-quote/"><strong>QUBT</strong></a>). It doesn&rsquo;t get much more direct than that. In all seriousness, the company is pioneering the production of photonic hardware solutions using non-linear quantum optics. This innovation should allow exponential acceleration in computing, machine learning, cybersecurity and other advanced fields.</p>



<p>According to Fortune Business Insights, the market itself is relatively small, landing at only $928.8 million last year. However, it&rsquo;s expanding at a tremendous clip; a compound annual growth rate (CAGR) of 32.1% to 2030, per analysts&rsquo; projections. If that rate holds true, the quantum computing sector <a href="https://www.fortunebusinessinsights.com/quantum-computing-market-104855#:~:text=The%20quantum%20computing%20market%20size,share%20of%2042.97%25%20in%202022.">could be worth approximately $6.53 billion</a>.</p>



<p>For context, QUBT stock only printed a market capitalization of just under $59 million. So, if the stars align, Quantum could easily rank among the millionaire-maker stocks.</p>



<p>Sure enough, <a href="https://finance.yahoo.com/news/7-analyst-backed-stocks-promising-000957206.html">Ascendiant&rsquo;s Woo also endorses QUBT, targeting $8.75</a> or around 1,015% up from Wednesday&rsquo;s close.</p>



<h2>Vivos (RDGL)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/10/biomedical-technology1600-300x169.png" alt="Modern Medical Research Laboratory with Computer, Microscope, Glassware with Biochemicals on the Desk. Scientific Lab Biotechnology Development Center Full of High-Tech Equipment. Biomedical technology stocks, RSLS Stock"><div>Source: Gorodenkoff / Shutterstock.com</div></div><p>If you want to know what a dedicated fanbase for a publicly traded security looks like, <a href="https://twitter.com/EnomotoMedia">check out my X account</a>. Here, you&rsquo;re going to find plenty of discussions and expressions of adoration for medical technology firm <strong>Vivos</strong> (OTCMKTS:<a href="https://investorplace.com/stock-quotes/rdgl-stock-quote/"><strong>RDGL</strong></a>). Yes, it&rsquo;s traded over the counter. Yes, it&rsquo;s a six-cent stock. No, it&rsquo;s not something out of the movie &ldquo;The Wolf of Wall Street.&rdquo;</p>



<p>Instead, what we have here is a radiation oncology specialist. Focusing on an advanced form of brachytherapy, Vivos utilizes radioactive materials (yttrium-90) to directly implement a high-dose treatment to the target area while imposing a minimal dosage to surrounding healthy tissue. Brachytherapy is already a promising therapeutic approach, which should see a 7.1% CAGR <a href="https://www.grandviewresearch.com/industry-analysis/brachytherapy-devices-market">to land at a value of $1.62 billion by 2030</a>.</p>



<p>Here&rsquo;s what&rsquo;s really intriguing about Vivos: it improves upon brachytherapy through a minimally invasive procedure that leverages a hydrogel solution to deliver the cancer-fighting therapeutic. Following the implementation, the hydrogel is safely absorbed by the body. Vivos appears unique in its brachytherapy-based approach. Therefore, I have personally put my money where my mouth is here.</p>



<p><strong><em>On Penny Stocks and Low-Volume Stocks:&#8239;</em></strong><em>With only the rarest exceptions,&nbsp;InvestorPlace&nbsp;does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s&nbsp;writers disclose this fact and warn readers of the risks.</em></p>



<p><strong><em>Read More:&#8239;</em></strong><a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank"><em>Penny Stocks &mdash;&nbsp;How to Profit Without Getting Scammed</em></a></p>



<p><em>On the date of publication, Josh Enomoto</em><em>&nbsp;held a LONG position in RDGL. </em><em>The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;</em><a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank"><em>Publishing Guidelines</em></a><em>.</em></p>
<div><p>A former senior business analyst for Sony Electronics, Josh Enomoto has helped broker major contracts with Fortune Global 500 companies. Over the past several years, he has delivered unique, critical insights for the investment markets, as well as various other industries including legal, construction management, and healthcare. Tweet him at @EnomotoMedia.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/07/venture-capitalist-predicts-this-chatgpt-announcement-will-shock-the-world/?cid=MKT744191&amp;eid=MKT766413">ChatGPT IPO Could Shock the World, Make This Move Before the Announcement</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
<p>The post <a href="https://investorplace.com/2024/02/3-stocks-to-turn-1000-into-1-million-february-2024/">3 Stocks to Turn $1,000 Into $1 Million: February 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

3 Stocks to Turn $1,000 Into $1 Million: February 2024

Vivos Inc (RDGL) has issued an update. Vivos, Inc. has renewed its Executive Employment Agreement with CEO Dr. Michael Korenko, effective January 1...

Vivos Inc Secures Leadership Continuity with CEO Contract Renewal

Catalyst Watch: Disney earnings, Apple iPad event and Fed speakers back on the circuit

AAPL

ABNB

AFRM

AMCX

ASCUF

AZTR

BYDDF

BYND

CABA

COST

CPNG

CPRI

CRSP

DCPH

DDOG

EDIT

FGEN

KNSL

KOPN

KSCP

LAZR

MBLY

MCBC

MNST

MSFT

NDAQ

NISTF

NKLA

NRGV

OILSF

PENMF

PLTR

QUBT

QUISF

RACE

RBLX

RDDT

RDGL

REGN

RIVN

SAVE

SHOP

SNAP

TCEHY

TSLA

UBER

UPST

VRTX

VSTO

VZIO

XIACF

ZYXI

Screenshot 2024-07-01 at 8.57.06 AM

Biotech

General

Vivos One Step Closer To Transforming Cancer Treatment With FDA Application To Start Human Trials For Pioneering Injectable Brachytherapy Device

Press Releases

Radiogel™ Precision Radionuclide Therapy™ Receives FDA Breakthrough Device Designation

Vivos Inc. Submits the Application to the FDA for Authority to Initiate Human Clinical Trials

Vivos Inc. Provides IDE Submission Status Update – Conversion to Pre-Sub Filing Accepted by the FDA

Vivos Inc. Extended its IsoPet® Precision Radionuclide TherapyTM to Exotics

Vivos Inc. Certifies New Clinic for IsoPet® Precision Radionuclide TherapyTM

Vivos

Comments

Vivos

Notizie

Ultime notizie per Vivos (OTC:RDGL) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO